Objective: To study the effects of epalrestat combined with taurine on the efficacy of cataract in diabetic patients and its effects on inflammation and oxidative stress factors. Methods: 90 cases(152 eyes) of diabetic cataracts were randomly divided into the observation group and the control group. The observation group consisted of 45 cases (75 eyes) and the control group consisted of 45 cases (77 eyes). Both groups were treated with phacoemulsification and intraocular lens implantation. The control group was given taurine eye drops, and the observation group was given epalrestat on the basis of the control group. Before and after treatment, daily visual acuity examination was performed using standard logarithmic visual acuity chart. The anterior segment complication was scored before and 3, 7, 14 days after surgery. Serum malondialdehyde (MDA), superoxide dismutase (SOD) and total antioxidant capacity (TAC) levels was measured before and after treatment. Quality of life (QOL) assessment was performed using the QOL questionnaire from the National Ophthalmology Institute. Results: The proportion of corrected visual acuity of 0.5 in the observation group was significantly higher than that in the control group (P<0.05). The results of variance analysis of repeated measurements showed that the synthetical evaluation of anterior segment symptoms in the control group and the observation group decreased in 3, 7 and 14 days after operation, while the synthetical evaluation of anterior segment symptoms in the observation group was lower than that in the control group, the difference was significant (P<0.001). The difference of MDA, SOD and TAC levels before and after treatment in the observation group was higher than that in the control group (P<0.05). The quality of life score in the observation group was significantly higher than that in the control group (P<0.05). Conclusion: The combination of epalrestat and taurine after operation can double the regulation of intraocular osmotic pressure and reduce the stress damage caused by surgery, which is conducive to postoperative visual recovery, reduce postoperative complications and improve the prognosis of patients.
 SIVAPRASAD S,BUNCE C,CROSBY-NWAOBI R, et al.Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery[J].Cochrane Database Syst Rev,2005,25(1):CD004239.
 NIROGI R, KANDIKERE V, AJJALA D R,et al.LC-MS/MS method for the quantification of aldose reductase inhibitor-Epalrestat and application to pharmacokinetic study[J].J Pharm Biomed Anal,2013,74(2):227-234.
 闫文亮.牛磺酸的生物学功能及其在眼用制剂中的应用分析[J].中国药房,2007, 18(30):2390-2391.
 袁媛,邱霞.糖尿病性白内障发病机制及治疗研究进展[J].转化医学杂志,2014,3(4):244-245, 256.